In silico assessment of potential leads identified from Bauhinia rufescens Lam. as α-glucosidase and α-amylase inhibitors

References

• Thomford NE, Senthebane DA, Rowe A, et al. Natural products for drug discovery in the 21st century: innovations for novel drug discovery. IJMS. 2018;19(6):1578.
   Web of Science ®Google Scholar
• Patridge E, Gareiss P, Kinch MS, et al. An analysis of FDA-approved drugs: natural products and their derivatives. Drug Discov Today. 2016;21(2):204–207.
   PubMed Web of Science ®Google Scholar
• Blass B. Basic principles of drug discovery and development. 1st ed. Amsterdam: Academic Press; 2015.
   Google Scholar
• Yuan H, Ma Q, Ye L, et al. The traditional medicine and modern medicine from natural products. Molecules. 2016;21(5):559.
   PubMed Web of Science ®Google Scholar
• Hefti FF. Requirements for a lead compound to become a clinical candidate. BMC Neurosci. 2008;9(Suppl 3):S7.
   PubMedGoogle Scholar
• Huang SY, Zou X. Advances and challenges in protein-ligand docking. Int J Mol Sci. 2010;11(8):3016–3034.
   PubMed Web of Science ®Google Scholar
• Petrovska BB. Historical review of medicinal plants' usage. Pharmacogn Rev. 2012;6(11):1–5.
   PubMedGoogle Scholar
• Carvalho JC, Santos LS, Viana EP, et al. Anti-inflammatory and analgesic activities of the crude extracts from stem bark of Bauhinia guianensis. Pharm Bio. 1999;37(4):281–284.
   Web of Science ®Google Scholar
• Cipak L, Grausova L, Miadokova E, et al. Dual activity of triterpenoids: apoptotic versus antidifferentiation effects. Arch Toxicol. 2006;80(7):429–435.
   PubMed Web of Science ®Google Scholar
• Deepak M, Handa SS. Antiinflammatory activity and chemical composition of extracts of Verbena officinalis. Phytother Res. 2000;14(6):463–465.
   PubMed Web of Science ®Google Scholar
• Kittakoop P, Kirtikara K, Tanticharoen M, et al. Antimalarial preracemosols A and B, possible biogenetic precursors of racemosol from Bauhinia malabarica Roxb. Phytochem. 2000;55(4):349–352.
   PubMed Web of Science ®Google Scholar
• Rao AV, Gurfinkel DM. The bioactivity of saponins: triterpenoid and steroidal glycosides. Drug Metabol Drug Interact. 2000;17:211–235.
   PubMedGoogle Scholar
• Songarsa S, Rajviroongit S, Sae‐Tang D, et al. New racemosol derivatives as potent cyclooxygenase (COX) inhibitors. Chem Biodivers. 2005;2(12):1635–1647.
   PubMed Web of Science ®Google Scholar
• Osman W, Khalid H, Muddathir A, et al. HPTLC Fingerprints profile and identification of antidiabetic and antioxidant leads from Bauhinia rufescens (L.). Advan Pharmacol Pharma Sci. 2020;2020:1–18.
   Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.
   PubMed Web of Science ®Google Scholar
• Organic Chemistry Portal. 2019 [Accessed Mar 13]. Available from: http://www.organic-chemistry.org/prog/peo/.
   Google Scholar
• Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1997;18(15):2714–2723.
   PubMed Web of Science ®Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–2791.
   PubMed Web of Science ®Google Scholar
• Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem. 1998;19(14):1639–1662.
   Web of Science ®Google Scholar
• Goddard TD1, Huang CC, Ferrin TE. Software extensions to UCSF chimera for interactive visualization of large molecular assemblies. Structure. 2005;13(3):473–482.
   PubMed Web of Science ®Google Scholar
• Hermans MMP, Kroos MA, van Beeumen J, et al. Human lysosomal alpha-glucosidase. Characterization of the catalytic site. " J Biol Chem . 1991;266:13507–13512.
   PubMed Web of Science ®Google Scholar
• Roig-Zamboni V, Cobucci-Ponzano B, Iacono R, et al. Structure of human lysosomal acid α-glucosidase-a guide for the treatment of Pompe disease. Nat Commun. 2017;8(1):1111–1111.
   PubMedGoogle Scholar
• Williams JA. Amylase. Pancreapedia: Exocrine Pancreas Knowledge Base; 2017.
   Google Scholar
• Brayer GD, Luo Y, Withers SG. The structure of human pancreatic alpha-amylase at 1.8 A resolution and comparisons with related enzymes. Protein Sci. 1995;4(9):1730–1742.
   PubMed Web of Science ®Google Scholar
• Brayer GD, Sidhu G, Maurus R, et al. Subsite mapping of the human pancreatic alpha-amylase active site through structural, kinetic, and mutagenesis techniques. Biochem. 2000;39(16):4778–4791.
   PubMed Web of Science ®Google Scholar
• Washim K, Rabea P, Karishma C, et al. Hypoglycemic potential of aqueous extract of Moringa oleifera leaf and in vivo GC-MS metabolomics. Front Pharmacol. 2017;8:1–16.
   PubMed Web of Science ®Google Scholar
• Washim K, Karishma C, Varisha A, et al. Chromatographic profiling of Pancharishta at different stages of its development using HPTLC, HPLC, GC–MS and UPLC–MS. Phytochem Lett. 2017;20:391–400.
   Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1–3):3–26.
   PubMed Web of Science ®Google Scholar
• Montanari F, Ecker GF. Prediction of drug-ABC-transporter interaction–recent advances and future challenges. Adv Drug Deliv Rev. 2015;86:17–26.
   PubMed Web of Science ®Google Scholar
• Testa B, Kraemer SD. The biochemistry of drug metabolism – an introduction. Chem Biodivers. 2007;4(3):257–405.
   PubMed Web of Science ®Google Scholar
• Hollenberg PF. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev. 2002;34(1–2):17–35.
   PubMed Web of Science ®Google Scholar
• Huang S-M, Strong JM, Zhang L, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol. 2008;48(6):662–670.
   PubMed Web of Science ®Google Scholar
• Patil R, Da S, Stanley A, et al. Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. PLoS One. 2010;5(8):e12029.
   PubMed Web of Science ®Google Scholar